News Search Results

Displaying Results 3876-3900 of 4535 "biotechnology"

Jun 30, 2025, 14:25 ET Europe Single-use Bioreactors Market to Reach $3.34 Billion by 2032, Growing at a CAGR of 15.3% from 2025, Says Meticulous Research®

Europe single-use bioreactors market is driven by rapid adoption of disposable technology in pharmaceutical and biotechnology industries, growing demand for biopharmaceuticals, substantial government support for bioproduction and biopharma products, and significant capacity

More news about: Meticulous Market Research Pvt. Ltd.


Jun 30, 2025, 14:14 ET North America LIMS Market to Reach $763.5 Million by 2032, Growing at a CAGR of 7.1% from 2025, Says Meticulous Research®

capabilities to meet the growing demand for efficient data management, regulatory compliance, and enhanced laboratory productivity across pharmaceutical, biotechnology, food & beverage, and environmental testing sectors. For more comprehensive insights, download the FREE report sample: 

More news about: Meticulous Market Research Pvt. Ltd.


Jun 30, 2025, 12:42 ET Rubin and Rudman Partner Susan Grandis Named a 2025 "Go To Family Law Lawyer" by Massachusetts Lawyers Weekly

Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational

More news about: Rubin and Rudman


Jun 30, 2025, 12:29 ET Regenerative Medicine Market to Reach $45.66 Billion by 2032, Growing at a CAGR of 22.0% from 2025, Says Meticulous Research®

Strategic Market Opportunities and Innovation Drivers The market presents extraordinary growth opportunities through advanced biotechnology integration, personalized medicine development, and expansion of therapeutic applications across multiple disease areas. Companies are discovering

More news about: Meticulous Market Research Pvt. Ltd.


Jun 30, 2025, 11:40 ET Leather for Automotive Seats Market Size Expected to Reach USD 69.12 Bn 2031, Growing at CAGR of 5.3%, Booming Automotive Industry Fuels Growth | The Insight Partners

consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact

More news about: The Insight Partners


Jun 30, 2025, 11:30 ET Metagenomics Market to Reach $7.78 Billion by 2032, Growing at a CAGR of 15.8% from 2025, Says Meticulous Research®

programs, and established biotechnology ecosystem facilitating rapid innovation and commercialization of metagenomic solutions. Asia-Pacific emerges as a high-growth region during the forecast period, propelled by expanding biotechnology sectors, increasing government

More news about: Meticulous Market Research Pvt. Ltd.


Jun 30, 2025, 11:15 ET Protein Expression Market to Reach $5 Billion by 2032, Growing at a CAGR of 7.6% from 2025, Says Meticulous Research®

emerging opportunities in underpenetrated economies, and the critical need for advanced protein synthesis technologies across pharmaceutical research, biotechnology development, and industrial applications. The industry is experiencing transformational growth through advanced mammalian cell expression

More news about: Meticulous Market Research Pvt. Ltd.


Jun 30, 2025, 11:01 ET Gallant Closes $18 Million Series B to Bring Ready-to-Use Stem Cell Therapies for Pets to Market

Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, announced the successful closing of its $18 million

More news about: Gallant


Jun 30, 2025, 11:00 ET Whole Genome Sequencing Market to Reach $8.35 Billion by 2032, Growing at a CAGR of 15.4% from 2025, Says Meticulous Research®

Innovation The global whole genome sequencing market features an innovative competitive ecosystem comprising specialized genomics companies, biotechnology firms, pharmaceutical companies, and integrated healthcare technology providers. This diverse landscape fosters rapid technological advancement

More news about: Meticulous Market Research Pvt. Ltd.


Jun 30, 2025, 10:45 ET Sterilization Equipment Market to Reach $29.2 Billion by 2032, Growing at a CAGR of 8.2% from 2025, Says Meticulous Research®

efficiency, precision, and environmental sustainability in sterilization processesPharmaceutical & Biotechnology Growth: Expanding demand from pharmaceutical and biotechnology industries for specialized sterilization solutions supporting complex biologics manufacturing and sterile processing

More news about: Meticulous Market Research Pvt. Ltd.


Jun 30, 2025, 10:30 ET Neurogenomics Market to Reach $5.48 Billion by 2032, Growing at a CAGR of 17% from 2025, Says Meticulous Research®

disorders. This segment is also expected to register the highest CAGR during the forecast period. Based on end user, the Pharmaceutical & Biotechnology Companies segment leads the market with 44% share in 2025, reflecting high adoption of advanced technologies for research, high availability of

More news about: Meticulous Market Research Pvt. Ltd.


Jun 30, 2025, 10:15 ET IVD Assay Development Market to Reach $9.15 Billion by 2032, Growing at a CAGR of 8.1% from 2025, Says Meticulous Research®

development market features a diverse competitive ecosystem comprising specialized contract development organizations, pharmaceutical companies, biotechnology firms, and integrated diagnostic solutions providers. This dynamic landscape fosters rapid technological advancement through sophisticated assay

More news about: Meticulous Market Research Pvt. Ltd.


Jun 30, 2025, 10:06 ET AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program

June 30, 2025 /PRNewswire/ -- AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapies for hematologic cancers and autoimmune diseases, today announced it has been awarded a grant of

More news about: AvenCell Therapeutics, Inc.


Jun 30, 2025, 10:01 ET Autoimmune Disease Diagnostics Market to Reach $11.45 Billion by 2032, Growing at a CAGR of 7.5% from 2025, Says Meticulous Research®

Innovation The global autoimmune disease diagnostics market features an innovative competitive ecosystem comprising specialized diagnostic companies, biotechnology firms, and integrated healthcare technology providers. This diverse landscape fosters rapid technological advancement through sophisticated biosensor

More news about: Meticulous Market Research Pvt. Ltd.


Jun 30, 2025, 09:00 ET Kyverna Therapeutics Announces Appointment of New Chief Financial Officer

responsible for building and managing the west coast life sciences and biotechnology investment banking business. He also held roles as Managing Director of Investment Banking in the Global Healthcare Group at UBS, focused on the biotechnology sector, and as Managing Director of Investment Banking at Leerink

More news about: Kyverna Therapeutics


Jun 30, 2025, 09:00 ET UL Research Institutes' Chemical Insights Names New Executive Director

director of the Center for Computational Toxicology and Exposure. Before joining the EPA, he performed bioinformatics and genomics research in the biotechnology sector and gained experience in high-throughput screening and in vitro assay development in the biopharma sector. He also worked as an investigator

More news about: UL Research Institutes


Jun 30, 2025, 09:00 ET Noul Publishes Its Fifth Sustainability Report, Outlining a Vision for Growth and a Decade of Breakthroughs

solutions, and realize those possibilities. Noul has commercialized the world's first AI-powered diagnostic lab, miLab™, through convergence of AI, biotechnology, and compact robotics. The miLab™ Platform is the only solution that fully automates the microscopic diagnostic process—from sample preparation

More news about: Noul


Jun 30, 2025, 09:00 ET AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing

More news about: Amgen


Jun 30, 2025, 08:31 ET AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology

June 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today announced a definitive agreement under

More news about: AbbVie


Jun 30, 2025, 08:30 ET Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline

information on the durability of Xanamem's benefits." About Actinogen Medical Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong

More news about: Actinogen Medical Limited


Jun 30, 2025, 08:00 ET Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase

More news about: Intensity Therapeutics Inc.


Jun 30, 2025, 08:00 ET Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

June 30, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,

More news about: Tyra Biosciences


Jun 30, 2025, 08:00 ET Avant Technologies and JV Partner, Ainnova, Prepare for Key FDA Milestone with Next Week's Pre-Submission Meeting

solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is possible in AI and biotechnology, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about

More news about: Avant Technologies Inc.


Jun 30, 2025, 07:45 ET ARTAN Bio Partners with Syenex VivoCell Platform for Precision in vivo Delivery of Next-Generation Codon Suppressors for Aging

ARTAN Bio, a community-backed biotechnology company developing therapeutics to reverse epigenetic changes associated with aging and age-related disease, and

More news about: Syenex


Jun 30, 2025, 07:00 ET Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

acquisition of the Company or the exclusive license of pelareorep. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized

More news about: Oncolytics Biotech® Inc.


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.